The role of hypoxic mesenchymal stem cells in tumor immunity

Tian, Ye; Fang, Jian; Zeng, Fanpeng; Chen, Yongqiang; Pei, Yunfeng; Gu, Feng; Chen, Ding; Niu, Guoping; Gu, Bing

doi:10.1016/j.intimp.2022.109172

Cited by 6 publications

(1 citation statement)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As tumor progresses, the levels of inflammation and hypoxia in TME increase, leading to the potential recruitment of MSCs from other tissues to further facilitate tumor development. 68 , 69 Although the impact of CA‐MSCs on both tumors and TME has been well documented, the specific origins of MSCs recruited by tumor cells remain unclear. Current evidence suggests that bone marrow may serve as a crucial tissue source of MSCs recruited by tumor cells.…”

Section: Mscs In the Tmementioning

confidence: 99%

The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics

Tang,

Chen,

Wang

et al. 2024

MedComm

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are recruited by malignant tumor cells to the tumor microenvironment (TME) and play a crucial role in the initiation and progression of malignant tumors. This role encompasses immune evasion, promotion of angiogenesis, stimulation of cancer cell proliferation, correlation with cancer stem cells, multilineage differentiation within the TME, and development of treatment resistance. Simultaneously, extensive research is exploring the homing effect of MSCs and MSC‐derived extracellular vesicles (MSCs‐EVs) in tumors, aiming to design them as carriers for antitumor substances. These substances are targeted to deliver antitumor drugs to enhance drug efficacy while reducing drug toxicity. This paper provides a review of the supportive role of MSCs in tumor progression and the associated molecular mechanisms. Additionally, we summarize the latest therapeutic strategies involving engineered MSCs and MSCs‐EVs in cancer treatment, including their utilization as carriers for gene therapeutic agents, chemotherapeutics, and oncolytic viruses. We also discuss the distribution and clearance of MSCs and MSCs‐EVs upon entry into the body to elucidate the potential of targeted therapies based on MSCs and MSCs‐EVs in cancer treatment, along with the challenges they face.

show abstract

Section: Mscs In the Tmementioning

confidence: 99%